Results 51 to 60 of about 276,970 (298)

Three Years Survival Rate of Epithelial Ovarian Cancer Patients in Dr. Kariadi Hospital, Semarang, Central Java [PDF]

, 2016
Objectives: to determine the association between prognostic factors of ovarian cancer with a 3-years survival rate of epithelial ovarian cancer patients.Material and Method: Retrospective cohort study was conducted in 90 patients (during 2012) at Dr ...
Damayanti, I. N. (Indah), Kusumastuti, E. H. (Etty), Yulianti, I. (Indra)   +2 more
core  

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

LncRNA PCGEM1 Induces Ovarian Carcinoma Tumorigenesis and Progression Through RhoA Pathway

Cellular Physiology and Biochemistry, 2018
Background/Aims: Prostate cancer gene expression marker 1 (PCGEM1) is a long noncoding RNA (lncRNA) and is well known as a promoter in prostate cancer and osteoarthritis synoviocytes. However, the role PCGEM1 plays in epithelial ovarian cancer is unknown.
Shuo Chen, Li-li Wang, Kai-xuan Sun, Yao Liu, Xue Guan, Zhi-hong Zong, Yang Zhao   +6 more
doaj   +1 more source

Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma [PDF]

, 2003
BACKGROUND: We wished to evaluate the clinical response following ATP-Tumor Chemosensitivity Assay (ATP-TCA) directed salvage chemotherapy in a series of UK patients with advanced ovarian cancer. The results are compared with that of a similar assay used
A du Bois, A Villa, Alan Lamont, AN Gordon, Andrew C Hindley, B Lund, Bernard R Higgins, Christian M Kurbacher, CM Kurbacher, CM Kurbacher, DD Von Hoff, DD Von Hoff, DL Clarke-Pearson, DS Ettinger, EM Hunter, Federica Di Nicolantonio, G Blackledge, G Konecny, GJ Rustin, GJ Rustin, IA Cree, IA Cree, IA Cree, Ian A Cree, J Kaern, JS Berek, JT Thigpen, KA Donovan, Louise A Knight, M Breidenbach, M Breidenbach, M Gore, M Harries, M Markman, M Markman, M Markman, M Markman, Martin Gore, ME Gore, ME Gore, ME van der Burg, MH Neale, Michael H Neale, MJ Piccart, ML Hensley, N Myatt, OM Grecu, P Hanjani, P Therasse, Pauline A Whitehouse, PE Andreotti, PG Rose, RD Petty, Richard Osborne, Robert T. Greenlee, Sanjay Sharma, Stuart J Mercer, T Meyer, U Kurbacher CM Stier, WP McGuire   +59 more
core   +4 more sources

Tumor and germline testing with next generation sequencing in epithelial ovarian cancer: a prospective paired comparison using an 18‐gene panel

Molecular Oncology, EarlyView.
Genetic testing in epithelial ovarian cancer includes both germline and tumor‐testing. This approach often duplicates resources. The current prospective study assessed the feasibility of tumor‐first multigene testing by comparing tumor tissue with germline testing of peripheral blood using an 18‐gene NGS panel in 106 patients.
Elisabeth Spenard, Cristina Mitric, Melanie Care, Tracy L. Stockley, Raymond H. Kim, Jeanna McCuaig, Blaise Clarke, Laura Ranich, Clare Sheen, Sarah E. Ferguson, Liat Hogen, Taymaa May, Marcus Q. Bernardini   +12 more
wiley   +1 more source

Apoptotic and chemotherapeutic properties of iron(III)-salophene in an ovarian cancer animal model [PDF]

, 2008
The cytotoxicity of organometallic compounds iron(III)-, cobalt(III)-, manganese(II)-, and copper(II)-salophene (-SP) on platinum-resistant ovarian cancer cell lines was compared. Fe-SP displayed selective cytotoxicity (IC 50 at ∼1 μM) against SKOV-3 and
Alptürk, O, Brard, L, Kyu, KK, Lange, TS, Luisi, BS, McCourt, C, Singh, AP, Singh, RK, Strongin, RM   +8 more
core   +3 more sources

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

SERPIND1 Affects the Malignant Biological Behavior of Epithelial Ovarian Cancer via the PI3K/AKT Pathway: A Mechanistic Study

Frontiers in Oncology, 2019
Serpin family D member 1 (SERPIND1) belongs to the serine protease inhibitor family. Its role in cancers has gradually attracted interest from researchers in recent years.
Qian Guo, Qian Guo, Qian Guo, Liancheng Zhu, Caixia Wang, Shuang Wang, Xin Nie, Juanjuan Liu, Qing Liu, Yingying Hao, Xiao Li, Bei Lin, Bei Lin, Bei Lin   +13 more
doaj   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Weekly versus three weeks chemotherapy for advanced ovarian cancer. A meta-analysis [PDF]

, 2016
Aim: Three weeks paclitaxel and carboplatin has been considered the standard of care for primary treatment of ovarian cancer (OC). Whether weekly therapy will further improve the clinical outcomes or not is still unclear.
De Felice, Francesca, Marchetti, Claudia, Monti, Marco, Musella, Angela, Musio, Daniela, Muzii, Ludovico, Palaia, Innocenza, Panici, Pierluigi Benedetti, Tombolini, Vincenzo   +8 more
core   +1 more source